Skip to main content
. 2015 Jan 28;13(2):741–755. doi: 10.3390/md13020741

Table 4.

Changes in erythrocyte membrane fatty acids content.

Cholecalciferol with Olive Oil Cholecalciferol with Omega-3 FA
Baseline 12 Weeks Baseline 12 Weeks
Saturated 47.0 ± 8.6 40.4 ± 0.5 45.1 ± 9.8 41.4 ± 1.2
Myristic 0.5 ± 0.2 0.3 ± 0.1 * 0.5 ± 0.1 0.4 ± 0.1
Palmitic 25.9 ± 4.4 21.9 ± 0.5 * 25.4 ± 5.1 23.1 ± 1.4
Stearic 20.0 ± 4.2 17.7 ± 0.6 18.8 ± 4.7 17.4 ± 0.6
Lignoceric 0.6 ± 0.2 0.4 ± 0.1 * 0.5 ± 0.2 0.5 ± 0.2
Monounsaturated 17.8 ± 1.9 16.1 ± 0.9 * 17.5 ± 1.5 15.9 ± 1.0 *
Palmitoleic 0.8 ± 0.4 0.6 ± 0.2 0.7 ± 0.2 0.6 ± 0.2
Oleic 16.0 ± 1.6 14.6 ± 0.8 15.8 ± 1.5 14.5 ± 1.0 *
Polyunsaturated 34.0 ± 10.3 42.5 ± 0.7 36.2 ± 11.1 41.7 ± 1.5
Omega-6 23.3 ± 5.0 28.2 ± 2.8 25.8 ± 7.0 24.6 ± 2.3
Linoleic 9.5 ± 1.3 9.2 ± 1.5 10.0 ± 2.1 9.3 ± 1.4
AA 10.0 ± 4.0 14.1 ± 1.2 * 11.2 ± 4.6 11.3 ± 1.8
Omega-3 10.8 ± 5.7 14.3 ± 2.3 10.4 ± 4.5 17.1 ± 2.7 *
Alpha-linolenic 0.4 ± 0.2 0.2 ± 0.1 * 0.2 ± 0.1 0.2 ± 0.1
EPA 1.6 ± 0.9 2.0 ± 0.9 1.3 ± 0.5 3.9 ± 1.4 *
DHA 6.9 ± 3.9 9.2 ± 1.5 6.6 ± 2.9 9.3 ± 1.2 *
Omega-3 index 8.4 ± 4.7 11.2 ± 2.1 7.8 ± 3.4 13.2 ± 2.2 *
AA/EPA 8.2 ± 4.6 8.9 ± 6.3 9.2 ± 3.6 3.5 ± 2.3 *
Omega-6/Omega-3 2.7 ± 1.3 2.1 ± 0.6 2.8 ± 1.1 1.5 ± 0.4 *
Total trans-fatty acid 0.93 ± 0.24 0.91 ± 0.12 0.91 ± 0.24 0.86 ± 0.14
Trans-palmitoleic acid 0.18 ± 0.06 0.16 ± 0.06 0.22 ± 0.03 0.16 ± 0.05 *
Trans-oleic acid 0.62 ± 0.18 0.53 ± 0.14 0.57 ± 0.17 0.54 ± 0.12
Trans-linoleic acid 0.31 ± 0.11 0.38 ± 0.17 0.34 ± 0.10 0.32 ± 0.08
18:2 n6tt 0.06 ± 0.03 0.10 ± 0.09 0.07 ± 0.06 0.05 ± 0.03
18:2 n6ct 0.10 ± 0.04 0.11 ± 0.02 0.05 ± 0.03 0.13 ± 0.06
18:2 n6tc 0.15 ± 0.07 0.16 ± 0.08 0.17 ± 0.03 0.14 ± 0.04

Data are expressed as the means ± SD. The nonparametric Wilcoxon exact rank sum test was used to compare baseline data with 12-week data. * p-value <0.05 (mean values are significantly different from baseline). Abbreviations: AA, arachidonic acid; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid.